Thank you for sharing!

Your article was successfully shared with the contacts you provided.

SEATTLE-Immunex Corp. plans to build a $500-million manufacturing plant–part of its BioNext Project–in Rhode Island. When completed, company officials say the facility will house the largest cell culture manufacturing center in the world.

“(This project) is a key element of the execution of our strategic plan designed to satisfy growing demand in existing and emerging markets,” says Peggy Phillips, executive vice president and chief operating officer at Immunex. “The construction of this new plant will make Immunex one of the world’s leaders in biotechnology manufacturing, a key goal given the success of our marketed products and our need for manufacturing pipeline products in the future.”

The BioNext Project involves an investment of approximately $500 million to construct the new facility, which will house the largest bioreactors ever used in the industry. Conceptual design of the facility is complete and the company anticipates beginning construction in the fourth quarter of this year, pending receipt of appropriate zoning and environmental permits. The project is expected to be licensed by regulatory authorities in 2005.

The BioNext Project will add to three other facilities that are producing, or will produce, ENBREL. Currently, Immunex is working with Wyeth-Ayerst Pharmaceuticals, a division of American Home Products Corporation to retrofit an existing manufacturing facility on the West Greenwich, RI site. AHP purchased the facility in 1999 to help meet the growing market demand for ENBREL. AHP has agreed to sell the site to Immunex. AHP also is building a facility in Grange Castle, Ireland that will manufacture ENBREL. ENBREL, a drug used in the treatment of arthritis patients, is currently produced by a contract manufacturer in Germany.

Want to continue reading?
Become a Free ALM Digital Reader.

Once you are an ALM digital member, you’ll receive:

  • Unlimited access to GlobeSt and other free ALM publications
  • Access to 15 years of GlobeSt archives
  • Your choice of GlobeSt digital newsletters and over 70 others from popular sister publications
  • 1 free article* every 30 days across the ALM subscription network
  • Exclusive discounts on ALM events and publications

*May exclude premium content
Already have an account?


Join GlobeSt

Don't miss crucial news and insights you need to make informed commercial real estate decisions. Join GlobeSt.com now!

  • Free unlimited access to GlobeSt.com's trusted and independent team of experts who provide commercial real estate owners, investors, developers, brokers and finance professionals with comprehensive coverage, analysis and best practices necessary to innovate and build business.
  • Exclusive discounts on ALM and GlobeSt events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com.

Already have an account? Sign In Now
Join GlobeSt

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.